Novo Nordisk is facing a massive wave of generic competitors to its injectable formulations of GLP-1 agonist semaglutide, used to treat diabetes and obesity, as a key patent in India is due to expire ...

Eli Lilly's market share in India's weight‑loss drug market fell to 56% in March from 61% in February. Novo Nordisk's market share remained steady at 25%. Indian generic drugmakers have launched 26 ...

The rapid entry of semaglutide generics is beginning to weigh on the growth of Eli Lilly’s tirzepatide brand Mounjaro, even as the broader market expands, data from pharma market intelligence and data ...

When news breaks, you need to understand what actually matters — and what to do about it. At Vox, our mission to help you make sense of the world has never been more vital. But we can’t do it on our ...

Generic dapagliflozin is indicated to lower heart failure hospitalization risk in type 2 diabetes with established cardiovascular disease or multiple risk factors, and to improve glycemic control ...

Patients in Canada have been paying between $300 and $400 a month for Ozempic and Wegovy, depending on the prescribed dose You can save this article by registering for free here. Or sign-in if you ...

Pharman giant Biocon on Thursday named longtime executive Shreehas Tambe as its Managing Director and CEO, effective 1 April, as the Indian drugmaker completes the integration of its biologics arm to ...

Strides Pharma Science has agreed to acquire and in license a portfolio of branded generic medicines from Sandoz, strengthening its presence across Sub Saharan Africa. The deal, valued at about 12 ...

Semaglutide is part of a group of medicines called GLP-1 receptor agonists, commonly used to manage type 2 diabetes. In recent years, it has also gained worldwide attention for helping with weight ...

India could soon get a lot thinner - at least in theory. On Friday the patent on semaglutide - the molecule behind Danish drugmaker Novo Nordisk's blockbuster weight-loss drugs Wegovy and Ozempic - ...

Over the last year, Sanofi has been busy reshaping itself to focus more on innovative drugs, including selling a controlling stake in its former consumer business and using those proceeds to strike a ...